|
1）三輪洋人．機能性ディスペプシアの考え方．日本消化器病学会雑誌．2012; 109: 1683-96
|
|
|
|
2）Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dog: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011; 336: 791-800
|
|
|
|
|
3）Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol. 2011; 666: 218-25
|
|
|
|
|
|
4）Tack J, Janssen P. Acotiamide (Z-338, YM443), a new drag for the treatment of functional dyspepsia. Expert Opert Opin Investig Drugs. 2011; 20: 701-12
|
|
|
|
|
|
5）Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012; 61: 821-8
|
|
|
|
|
|
6）Drossman DA. The functional gastrointestinal disorders and Rome III process. Gastroenterol. 2006; 130: 1377-90
|
|
|
|
|
|
7）Kusunoki H, Haruma K, Hata J, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012; 24: 540-5, e251-1
|
|
|
|
|
|
8）楠 裕明，塚本真知，神崎智子，他．FDの病態・症状と新規治療薬アコチアミドを使いこなすためのコツ．消化器の臨床．2013; 16: 603-7
|
|
|
|
|
|
9）Kindt S, Dubois D, Van Oudenhove L, et al. Relationship between symptom pattern, assessed by the PAGI-SYM questionnaire, and gastric sensorimotor dysfunction in functional dyspepsia. Neurogastroenterol Motil. 2009; 21; 1183-e105
|
|
|
|
|
|
10）Geeraerts B, Tack J. Functional dyspepsia: past, present, and future. J Gastroenterol. 2008; 43: 251-5
|
|
|
|
|
|
11）Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012; 27: 626-41
|
|
|
|
|
|
12）日本消化器病学会，編．機能性消化管疾患診療ガイドライン2014―機能性ディスペプシア（FD）．東京: 南江堂; 2014
|
|
|
|
|